53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
6 citations
,
November 2010 in “International Journal of Andrology” New oral testosterone formulations show potential for safer, effective hormone replacement in men with low testosterone.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
July 2015 in “Pharmacological Reports” Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.
3 citations
,
September 2021 in “EClinicalMedicine” ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
May 2025 in “Reactions Weekly” July 2025 in “Skin Appendage Disorders” Dutasteride microinfusion and microneedling both effectively treat male hair loss.
March 2023 in “JAAD case reports” Dutasteride and minoxidil helped regrow hair in a woman with breast cancer.
8 citations
,
January 1987 in “Gynecological Endocrinology” Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.
Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
7 citations
,
January 1994 in “Annual Reports in Medicinal Chemistry” Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
45 citations
,
August 2005 in “Bioorganic & medicinal chemistry” New compounds with carborane showed anti-androgen effects similar to flutamide.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
52 citations
,
April 2002 in “Brain Research” Lower allopregnanolone levels increase stress-related dopamine release in the brain.
10 citations
,
October 2018 in “Neurology Neuroimmunology & Neuroinflammation” Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.
Allopregnanolone may help reduce inflammation and symptoms related to post-finasteride syndrome.
11 citations
,
November 2011 in “Neuroreport” Paroxetine relieves pain by increasing allopregnanolone levels.
April 2016 in “The FASEB Journal” Blocking androgen receptors early in life increases estrogen levels and reduces sexual motivation in male rats.
January 2026 in “Elsevier eBooks” 45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
10 citations
,
February 2008 in “International Journal of Andrology” A combination of nanomilled oral testosterone and dutasteride normalized testosterone levels in men with low testosterone and is safe for short-term use.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Lithium and zinc together can reverse hair loss by targeting specific cells.
6 citations
,
August 2024 in “Steroids”
11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.